Table 1.
Countries represented in global survey of NIPT use
| Country name | Recruitment method | # invited | # participated |
|---|---|---|---|
| Argentina | Colleague | 1 | 1 |
| Australia | Colleague | 6 | 3 |
| Austria | Colleague | 1 | 0 |
| Belgium | Colleague | 1 | 1 |
| Brazil | Colleague | 1 | 0 |
| Burkina Faso | FIGO society | 1 | 0 |
| Cameroon | FIGO society | 1 | 0 |
| Canada | Colleague | 3 | 2 |
| Chile | Colleague | 2 | 1 |
| Cote d’Ivoire | FIGO society | 1 | 0 |
| Cyprus | Colleague | 1 | 1 |
| Czech Republic | Colleague | 1 | 4 |
| Denmark | Colleague | 2 | 0 |
| Egypt | FIGO society | 1 | 0 |
| Finland | Colleague | 1 | 1 |
| France | Colleague | 1 | 1 |
| Germany | Colleague | 1 | 2 |
| Greece | Colleague | 1 | 1 |
| Hong Kong (China) | Colleague | 1 | 5 |
| Hungary | Colleague | 1 | 1 |
| Iceland | Colleague | 1 | 0 |
| India | Colleague, FIGO society | 6 | 3 |
| Iran | FIGO society | 1 | 0 |
| Ireland | Colleague | 1 | 1 |
| Israel | Colleague | 1 | 2 |
| Italy | Colleague | 3 | 1 |
| Jordan | FIGO society | 1 | 0 |
| Lebanon | Colleague | 1 | 0 |
| Libya | FIGO society | 1 | 0 |
| Malaysia | FIGO society | 1 | 0 |
| Mexico | FIGO society | 1 | 1 |
| Netherlands | Colleague | 2 | 2 |
| Norway | Colleague | 2 | 1 |
| Portugal | Colleague | 3 | 2 |
| Qatar | Colleague | 1 | 1 |
| Saudi Arabia | FIGO society | 1 | 0 |
| Senegal | FIGO society | 1 | 0 |
| Singapore | Colleague | 2 | 1 |
| South Africa | FIGO society | 1 | 0 |
| Spain | Colleague | 1 | 0 |
| Sweden | Colleague | 2 | 1 |
| Switzerland | Colleague | 1 | 1 |
| Tunisia | FIGO society | 1 | 0 |
| Turkey | Colleague | 1 | 1 |
| United Arab Emirates | FIGO society | 1 | 0 |
| United Kingdom | Colleague | 3 | 4 |
| United States | Colleague | 9 | 3 |
|
| |||
| TOTAL | 78 | 49 | |
List of countries included in global survey of NIPT use. Two recruitment methods were used to invite participants to take the survey, direct email invitations to colleagues of the study investigators (LC, SC) (‘colleague’), and email invitations to member societies of the International Federation of Gynecology and Obstetrics (FIGO) (http://www.figo.org/our-members) in which NIPT is marketed12 (‘FIGO society’). Note that there may be more participants in a country than the number who were invited because some participants appear to have forwarded the survey to other colleagues in their country.